ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months
It is anticipated that Inflammasome ASC Inhibitor IC 100 will control chronic inflammation of obesity, attenuate comorbidities, and enhance weight loss.
| Ticker |
Sentiment |
Impact |
|
ZVSA
|
Neutral
|
11 %
|
|
VTYX
|
Neutral
|
3 %
|
|
NVO
|
Neutral
|
3 %
|
|
SNY
|
Neutral
|
3 %
|
